[Modification by lacidipine of the clastogenic effect of dioxidine in vivo].
The influence of lacidipine (0.1-10 mg/kg, intragastric) on the clastogenic effect of dioxidine (100 and 200 mg/kg, i.p.) under conditions of their single and repeated (five-fold, 24-h interval) administration was studied by the chromosome aberration assay in the metaphase bone marrow cells of BALB/c and C57BL/6 male mice. It was found that single (5 or 10 mg/kg) and repeated (10 mg/kg) introduction of lacidipine enhances the clastogenic effect of dioxidine in both genotypes. At the same time, a single treatment of C57BL/6 mice with 0.1 and 1 mg/kg of lacidipine sometimes significantly reduced the clastogenic effect of dioxidine (200 mg/kg). Thus, lacidipine exhibits a comutagen effect in vivo when administered at large doses (5 and 10 mg/kg) but not at small doses, where the drug sometimes acted as antimutagen in C57BL/6 mice.
Nesterova
E V
EV
Institute of Pharmacology, Russian Academy of Medical Sciences, Moscow, Russia.
Durnev
A D
AD
Seredenin
S B
SB
D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000633:toxicity*; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000633:toxicity*; D004095:Dihydropyridines / Q000494:pharmacology / Q000633:toxicity*; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009152:Mutagenicity Tests; D009153:Mutagens / Q000633:toxicity*; D011810:Quinoxalines / Q000633:toxicity*
D000975:Antioxidants; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D009153:Mutagens; D011810:Quinoxalines; C001077:dioxidine; C060285:lacidipine